Skip to main content
DMAC logo

DMAC

DiaMedica Therapeutics Inc.
$7.13 -0.51 (-6.68%) At close · Jul 16
Market Cap
$384.19M
Shares
53,883,345

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$500K
FY2018
Net Income
-$32.77M -34%
FY2025 Net Income FY2017–FY2025
Operating Margin
-1352.2%
FY2018
Operating Cash Flow
-$29.06M -31.6%
FY2025 Operating Cash Flow FY2017–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
$500K
$26.95M $24.61M $19.06M $13.11M $7.84M $8.77M $8.21M $7.9M $4.52M $3.21M
$9.79M $9.78M $7.62M $8.16M $6.16M $4.88M $4.49M $3.69M $2.74M $1.31M
$34.4M $26.68M $21.27M $14M $13.65M $12.7M $11.59M $7.26M $4.52M
-$36.74M -$34.4M -$26.68M -$21.27M -$14M -$13.65M -$12.7M -$11.59M -$6.76M -$4.52M
-1352.2%
$1.7M $1.67M $2.3M $1.95M
$1.66M $1.66M $2.27M $1.93M $353K $82K $434K $975K $1.11M $259K
-$35.07M -$32.74M -$24.41M -$19.34M -$13.65M -$13.56M -$12.27M -$10.62M -$5.65M -$4.26M
$29K $28K $30K $43K $28K $28K $27K $31K $80K
-$35.1M -$32.77M -$24.44M -$19.38M -$13.68M -$13.59M -$12.29M -$10.65M -$5.73M -$4.26M
-1146.8%
-$35.13M -$32.74M -$24.43M -$19.3M -$13.7M -$13.64M -$12.3M -$10.65M -$5.73M
USD/shares -$0.70 -$0.60 -$0.60 -$0.52 -$0.65
shares 46.98M 40.4M 32.57M 26.44M 20.77M 15.68M 11.99M 7.74M 5.94M
shares 20.77M 15.68M 11.99M 7.74M 5.94M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.53×
EV/EBIT
Biotechnology median 26.36×
P/E (TTM)
Biotechnology median 7.37×
Key facts CIK 1401040 CUSIP 25253X207 13F (30d) 3 filings 3 filers Visit website